Malignant Peritoneal Neoplasm: Clinical Trials

2 trials for Malignant Peritoneal Neoplasm, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 12Completed 2

Follow Malignant Peritoneal Neoplasm: new trials by email Literature Review of Malignant Peritoneal Neoplasm trials Research Report on Malignant Peritoneal Neoplasm

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm
Phase 1CompletedM.D. Anderson Cancer Center262018-09-212025-05-22
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel - Cervical Adenocarcinoma, Cervical Adenosarcoma
Phase 1CompletedMayo Clinic432014-02-242024-07-26

Narrower conditions

Endometrial Neoplasms (1)  ·  Fallopian Tube Neoplasms (1)  ·  Ovarian Neoplasms (1)  ·  Peritoneal Neoplasms (1)  ·  Uterine Cervical Neoplasms (1)

Broader conditions

Abdominal Neoplasms (1)  ·  Adnexal Diseases (1)  ·  Digestive System Diseases (1)  ·  Digestive System Neoplasms (1)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)  ·  Fallopian Tube Diseases (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Genital Diseases (1)  ·  Genital Diseases, Female (1)  ·  Genital Neoplasms, Female (1)  ·  Gonadal Disorders (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)

Interventions

130-nm albumin-bound paclitaxel (1)  ·  Albumin-Bound Paclitaxel (1)  ·  Bevacizumab (1)  ·  CTLA-4 Antigen (1)  ·  Disulfides (1)  ·  Immunoglobulin G (1)  ·  Ipilimumab (1)  ·  Nivolumab (1)  ·  Pharmacogenomic Variants (1)  ·  Taxes (1)

Sponsors

M.D. Anderson Cancer Center (1)  ·  Mayo Clinic (1)

Countries

United States (2)

Top investigators

Amir A Jazaeri (1)  ·  Matthew S. Block, M.D., Ph.D. (1)

Results publications

PMID 38471508